Niacin Lipid Profile Meta-analysis: What the Evidence Says
Niacin Lipid Profile Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixe
Quick Answer
Niacin Lipid Profile Meta analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public health sources, so conclusions should be framed as evidence aware guidance rather than medical advice.
Key Takeaways
- 01This page is generated only from sources stored in the Migaku evidence knowledge base.
- 02Current evidence mix: 2 preclinical study.
- 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
- 04This article is educational and does not replace care from a qualified clinician.
Niacin Lipid Profile Meta-analysis: What the Evidence Says
Quick Answer
Niacin Lipid Profile Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.
Key Takeaways
- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.
Evidence Map
| Source | Evidence type | Level | Date | Identifier |
|---|---|---|---|---|
| Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies | preclinical study | 4 | 2026-05-08 | 10.3389/fendo.2026.1761761 |
| Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update | preclinical study | 4 | 2026-03-12 | 10.3390/jcm15062179 |
What The Sources Report
- Hypertriglyceridemia (hyperTG) in pregnancy has been associated with numerous maternal and fetal complications, including preeclampsia, pregnancy-induced hypertension, preterm delivery, abnormal fetal birth weight, and acute pancreatitis-a severe condition requiring urgent intervention. [Chamerski Szymon (2026); evidence level 4]
- It is important to note that not all cases of hyperTG observed during pregnancy result from maladaptive metabolic changes. [Chamerski Szymon (2026); evidence level 4]
- Since its discovery over half a century ago, Lp(a) has attracted considerable interest due to its strong, genetically determined association with atherosclerotic cardiovascular disease (ASCVD), independent of traditional lipid risk factors. [Domański Igor (2026); evidence level 4]
- Elevated Lp(a) concentrations-particularly those above 50 mg/dL-have been strongly linked to an increased risk of myocardial infarction, ischemic stroke, peripheral artery disease, heart failure, and aortic valve stenosis. [Domański Igor (2026); evidence level 4]
How To Read This Evidence
Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.
Practical Interpretation
For niacin lipid profile meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.
Limits Of This First Pass
This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.
References
- Chamerski Szymon (2026). Navigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies. DOI: 10.3389/fendo.2026.1761761. PMCID: PMC13194070. PMID: 42181215. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13194070/
- Domański Igor (2026). Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update. DOI: 10.3390/jcm15062179. PMCID: PMC13027314. PMID: 41899103. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13027314/
Safety Note
Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.
FAQ
Frequently Asked Questions
Medically reviewed
Last reviewed July 29, 2026 by Migaku Evidence Review
